Abstract
Adalimumab (ADA) is approved for use in moderate to severe juvenile idiopathic arthritis (JIA) in patients (pts) ≥4 years (yrs) old in the US, EU, and Japan. Limited data are available in pts <4 yrs old.
Highlights
Adalimumab (ADA) is approved for use in moderate to severe juvenile idiopathic arthritis (JIA) in patients ≥4 years old in the US, EU, and Japan
JIA pts were treated with ADA 24 mg/m2 every other week +/- methotrexate for a minimum of 24 wks in an ongoing international, multicenter, open-label, phase 3b study until achieving the limit for age (≥4 yrs) and weight (≥15 kg)
32 pts were randomized; through wk 60, two pts withdrew due to aes (JIA worsening or flare) and 2 withdrew for other reasons
Summary
Adalimumab (ADA) is approved for use in moderate to severe juvenile idiopathic arthritis (JIA) in patients (pts) ≥4 years (yrs) old in the US, EU, and Japan. PReS-FINAL-2161: Safety and effectiveness of adalimumab in children with polyarticular juvenile idiopathic arthritis aged 2 to =4 years weighing
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
